ABT is trading 4% up at $94.11 after announcing a global licensing agreement with ALZpath to develop blood-based Alzheimer’s diagnostic tests using the pTau217 biomarker on its Alinity platforms.
- The partnership aims to create scalable diagnostic solutions, leveraging Abbott's existing global diagnostic infrastructure.
- Investors are reacting positively to the company's expansion into advanced Alzheimer’s testing and its continued leadership in diversified healthcare.
- The stock is currently outperforming a mixed broader market following the strategic announcement.